Stevanato leverages deep expertise in precision glass manufacturing combined with cutting-edge engineering to provide value-added solutions for injectable biologics and biosimilars. The company is strategically positioned around high-value solutions (now representing 49% of revenue), with significant capacity expansion underway at Latina and Fishers facilities to capitalize on growing demand for self-administration and ready-to-use drug platforms.
Cyborg Score Rationale
Strong fundamentals with 9% Q3 2025 revenue growth and 47% high-value solutions expansion. However, near-term headwinds include Engineering segment challenges (19% decline), capital intensity pressuring free cash flow, and customer concentration risk. Capacity expansion provides medium-term upside if utilization improves.
Top Insights
High-value solutions achieving record 49% of Q3 2025 revenue with 47% growth driven by Nexa syringes and EZ-fill vials, signaling successful product mix shift
FY2025 guidance of €1.16-1.19B revenue and 43-44% high-value mix indicates management confidence despite tariff and FX headwinds
Engineering segment facing 19% revenue headwinds with delayed order conversion, suggesting temporary operational challenges requiring resolution
Strategic partnerships expanding (Datwyler collaboration on large-volume drug delivery), positioning for biosimilars and self-administered therapy trends
Named Competitors
Prefillable Syringes & Glass Packaging — Leading supplier of containment solutions for pharma
Glass Containers — Precision glass packaging for pharmaceuticals
Engineering Services — Precision engineering for medical/pharma devices